{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:45:28Z","timestamp":1787237128988,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11030-024-11026-0","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T02:14:05Z","timestamp":1731982445000},"page":"4177-4201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3\u03b2 (GSK-3\u03b2) inhibitors: 3D-QSAR, virtual screening, docking, MM\/GBSA, EC, MD simulation studies"],"prefix":"10.1007","volume":"29","author":[{"given":"Desu Gayathri","family":"Niharika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam","family":"Salaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Amarendar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"11026_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42494-023-00136-1","volume":"5","author":"A Adamu","year":"2023","unstructured":"Adamu A, Chen R, Li A, Xue G (2023) Epilepsy in Asian countries. Acta Epileptol 5:25. https:\/\/doi.org\/10.1186\/s42494-023-00136-1","journal-title":"Acta Epileptol"},{"key":"11026_CR2","doi-asserted-by":"publisher","first-page":"1303531","DOI":"10.3389\/fneur.2023.1303531","volume":"14","author":"Y Shu","year":"2023","unstructured":"Shu Y, Wu Z, Yang X et al (2023) The burden of epilepsy in the People\u2019s Republic of China from 1990 to 2019: epidemiological trends and comparison with the global burden of epilepsy. Front Neurol 14:1303531. https:\/\/doi.org\/10.3389\/fneur.2023.1303531","journal-title":"Front Neurol"},{"key":"11026_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0163-7258(01)00122-X","volume":"90","author":"P Kwan","year":"2001","unstructured":"Kwan P, Sills GJ, Brodie MJ (2001) The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 90:21\u201334. https:\/\/doi.org\/10.1016\/S0163-7258(01)00122-X","journal-title":"Pharmacol Ther"},{"key":"11026_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","volume":"4","author":"BS Meldrum","year":"2007","unstructured":"Meldrum BS, Rogawski MA (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4:18\u201361. https:\/\/doi.org\/10.1016\/j.nurt.2006.11.010","journal-title":"Neurotherapeutics"},{"key":"11026_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrn1430","volume":"5","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, L\u00f6scher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553\u2013564. https:\/\/doi.org\/10.1038\/nrn1430","journal-title":"Nat Rev Neurosci"},{"key":"11026_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.20243","author":"JE Pina-Garza","year":"2024","unstructured":"Pina-Garza JE, Chez M, Cloyd J et al (2024) Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: consensus recommendations of an expert working group. Epileptic Disord. https:\/\/doi.org\/10.1002\/epd2.20243","journal-title":"Epileptic Disord"},{"key":"11026_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ebiom.2018.11.040","volume":"39","author":"M Urbanska","year":"2019","unstructured":"Urbanska M, Kazmierska-Grebowska P, Kowalczyk T et al (2019) GSK3\u03b2 activity alleviates epileptogenesis and limits GluA1 phosphorylation. EBioMedicine 39:377\u2013387. https:\/\/doi.org\/10.1016\/j.ebiom.2018.11.040","journal-title":"EBioMedicine"},{"key":"11026_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0065-7743(05)40009-3","volume":"40","author":"JW Benbow","year":"2005","unstructured":"Benbow JW, Helal CJ, Kung DW, Wager TT (2005) Glycogen synthase kinase-3 (GSK-3): a kinase with exceptional therapeutic potential. Annu Rep Med Chem 40:135\u2013147. https:\/\/doi.org\/10.1016\/S0065-7743(05)40009-3","journal-title":"Annu Rep Med Chem"},{"key":"11026_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"C Hooper","year":"2008","unstructured":"Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer\u2019s disease. J Neurochem 104:1433\u20131439. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05194.x","journal-title":"J Neurochem"},{"key":"11026_CR10","doi-asserted-by":"publisher","first-page":"118745","DOI":"10.1016\/j.bbamcr.2020.118745","volume":"1867","author":"T Jaworski","year":"2020","unstructured":"Jaworski T (2020) Control of neuronal excitability by GSK-3beta: epilepsy and beyond. Biochim Biophys Acta BBA-Mol Cell Res 1867:118745. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118745","journal-title":"Biochim Biophys Acta BBA-Mol Cell Res"},{"key":"11026_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s11064-015-1614-1","volume":"40","author":"C Huang","year":"2015","unstructured":"Huang C, Fu X-H, Zhou D, Li J-M (2015) The role of Wnt\/\u03b2-catenin signaling pathway in disrupted hippocampal neurogenesis of temporal lobe epilepsy: a potential therapeutic target? Neurochem Res 40:1319\u20131332. https:\/\/doi.org\/10.1007\/s11064-015-1614-1","journal-title":"Neurochem Res"},{"key":"11026_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.neuroscience.2015.10.051","volume":"311","author":"G Gangarossa","year":"2015","unstructured":"Gangarossa G, Sakkaki S, Lory P, Valjent E (2015) Mouse hippocampal phosphorylation footprint induced by generalized seizures: focus on ERK, mTORC1 and Akt\/GSK-3 pathways. Neuroscience 311:474\u2013483. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.10.051","journal-title":"Neuroscience"},{"key":"11026_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.neuroscience.2015.10.051","volume":"50","author":"N Crespo-Biel","year":"2007","unstructured":"Crespo-Biel N, Canudas AM, Camins A, Pallas M (2007) Kainate induces AKT, ERK and cdk5\/GSK3\u03b2 pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochem Int 50:435\u2013442. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.10.051","journal-title":"Neurochem Int"},{"key":"11026_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuropharm.2016.09.025","volume":"113","author":"CN-J Meunier","year":"2017","unstructured":"Meunier CN-J, Cancela J-M, Fossier P (2017) Lack of GSK3\u03b2 activation and modulation of synaptic plasticity by dopamine in 5-HT1A-receptor KO mice. Neuropharmacology 113:124\u2013136. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.09.025","journal-title":"Neuropharmacology"},{"key":"11026_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8607038","volume":"2016","author":"C Bonansco","year":"2016","unstructured":"Bonansco C, Fuenzalida M (2016) Plasticity of hippocampal excitatory-inhibitory balance: missing the synaptic control in the epileptic brain. Neural Plast 2016:1\u201313. https:\/\/doi.org\/10.1155\/2016\/8607038","journal-title":"Neural Plast"},{"key":"11026_CR16","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/ijms19041160","volume":"19","author":"M Medina","year":"2018","unstructured":"Medina M (2018) An overview on the clinical development of tau-based therapeutics. Int J Mol Sci 19:1160. https:\/\/doi.org\/10.3390\/ijms19041160","journal-title":"Int J Mol Sci"},{"key":"11026_CR17","first-page":"221","volume":"23","author":"X Liu","year":"2017","unstructured":"Liu X, Chen L, Chen Y (2017) N-methyl-D-aspartate receptors mediate epilepsy-induced axonal impairment and tau phosphorylation via activating glycogen synthase kinase-3\u03b2 and cyclin-dependent kinase 5. Discov Med 23:221\u2013234","journal-title":"Discov Med"},{"key":"11026_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fncel.2020.00019","volume":"14","author":"D Toral-Rios","year":"2020","unstructured":"Toral-Rios D, Pichardo-Rojas PS, Alonso-Vanegas M, Campos-Pe\u00f1a V (2020) GSK3\u03b2 and tau protein in Alzheimer\u2019s disease and epilepsy. Front Cell Neurosci 14:19. https:\/\/doi.org\/10.3389\/fncel.2020.00019","journal-title":"Front Cell Neurosci"},{"key":"11026_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1034\/j.1399-5618.2002.40201.x","volume":"4","author":"X Li","year":"2002","unstructured":"Li X, Bijur GN, Jope RS (2002) Glycogen synthase kinase-3\u03b2, mood stabilizers, and neuroprotection. Bipolar Disord 4:137\u2013144. https:\/\/doi.org\/10.1034\/j.1399-5618.2002.40201.x","journal-title":"Bipolar Disord"},{"key":"11026_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2174\/138955751512150731113549","volume":"15","author":"R Ali","year":"2015","unstructured":"Ali R, Ahmed Khan M, Siddiqui N (2015) Past, present and future of antiepileptic drug therapy-finding a place for heterocyclics. Mini Rev Med Chem 15:1024\u20131050","journal-title":"Mini Rev Med Chem"},{"key":"11026_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejmech.2016.04.077","volume":"120","author":"MF Khan","year":"2016","unstructured":"Khan MF, Alam MM, Verma G et al (2016) The therapeutic voyage of pyrazole and its analogs: a review. Eur J Med Chem 120:170\u2013201. https:\/\/doi.org\/10.1016\/j.ejmech.2016.04.077","journal-title":"Eur J Med Chem"},{"key":"11026_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/molecules23010134","volume":"23","author":"K Karrouchi","year":"2018","unstructured":"Karrouchi K, Radi S, Ramli Y et al (2018) Synthesis and pharmacological activities of pyrazole derivatives: a review. Molecules 23:134. https:\/\/doi.org\/10.3390\/molecules23010134","journal-title":"Molecules"},{"key":"11026_CR23","doi-asserted-by":"publisher","first-page":"94786","DOI":"10.1039\/C5RA17391D","volume":"5","author":"S Viveka","year":"2015","unstructured":"Viveka S, Shama P, Naveen S et al (2015) Design, synthesis, anticonvulsant and analgesic studies of new pyrazole analogues: a Knoevenagel reaction approach. RSC Adv 5:94786\u201394795. https:\/\/doi.org\/10.1039\/C5RA17391D","journal-title":"RSC Adv"},{"key":"11026_CR24","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/molecules26051202","volume":"26","author":"X Li","year":"2021","unstructured":"Li X, Yu Y, Tu Z (2021) Pyrazole scaffold synthesis, functionalization, and applications in Alzheimer\u2019s disease and Parkinson\u2019s disease treatment (2011\u20132020). Molecules 26:1202. https:\/\/doi.org\/10.3390\/molecules26051202","journal-title":"Molecules"},{"key":"11026_CR25","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1016\/j.bmcl.2007.09.017","volume":"17","author":"K Paruch","year":"2007","unstructured":"Paruch K, Dwyer MP, Alvarez C et al (2007) Pyrazolo [1, 5-a] pyrimidines as orally available inhibitors of cyclin-dependent kinase 2. Bioorg Med Chem Lett 17:6220\u20136223. https:\/\/doi.org\/10.1016\/j.bmcl.2007.09.017","journal-title":"Bioorg Med Chem Lett"},{"key":"11026_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molstruc.2012.05.018","volume":"1024","author":"F Wang","year":"2012","unstructured":"Wang F, Liu M, Liu J (2012) In silico prediction of inhibitory effects of pyrazol-5-one and indazole derivatives on GSK3\u03b2 kinase enzyme. J Mol Struct 1024:94\u2013103. https:\/\/doi.org\/10.1016\/j.molstruc.2012.05.018","journal-title":"J Mol Struct"},{"key":"11026_CR27","doi-asserted-by":"publisher","first-page":"108035","DOI":"10.1016\/j.compbiolchem.2024.10803","volume":"110","author":"S Pandiyan","year":"2024","unstructured":"Pandiyan S, Wang L (2024) In-silico design of novel potential HDAC inhibitors from indazole derivatives targeting breast cancer through QSAR, molecular docking and pharmacokinetics studies. Comput Biol Chem 110:108035. https:\/\/doi.org\/10.1016\/j.compbiolchem.2024.10803","journal-title":"Comput Biol Chem"},{"key":"11026_CR28","doi-asserted-by":"publisher","first-page":"153412","DOI":"10.1016\/j.tox.2022.153412","volume":"485","author":"A Rosell-Hidalgo","year":"2023","unstructured":"Rosell-Hidalgo A, Moore AL, Ghafourian T (2023) Prediction of drug-induced mitochondrial dysfunction using succinate-cytochrome c reductase activity, QSAR and molecular docking. Toxicology 485:153412. https:\/\/doi.org\/10.1016\/j.tox.2022.153412","journal-title":"Toxicology"},{"key":"11026_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/minf.201000061","volume":"29","author":"A Tropsha","year":"2010","unstructured":"Tropsha A (2010) Best Practices for QSAR model development, validation, and exploitation. Mol Inform 29:476\u2013488. https:\/\/doi.org\/10.1002\/minf.201000061","journal-title":"Mol Inform"},{"key":"11026_CR30","doi-asserted-by":"publisher","first-page":"120250","DOI":"10.1016\/j.molliq.2022.120250","volume":"366","author":"S Krishna","year":"2022","unstructured":"Krishna S, Murthy TK, Divyashri G et al (2022) Pharmacoinformatics based screening of combined synthetic and natural compounds to identify novel and in silico potential Bcl-2 inhibitors. J Mol Liq 366:120250. https:\/\/doi.org\/10.1016\/j.molliq.2022.120250","journal-title":"J Mol Liq"},{"key":"11026_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jsps.2022.04.003","volume":"30","author":"RL Bakal","year":"2022","unstructured":"Bakal RL, Jawarkar RD, Manwar JV et al (2022) Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual screening, molecular docking, MD simulation and MMGBSA approaches. Saudi Pharm J 30:693\u2013710. https:\/\/doi.org\/10.1016\/j.jsps.2022.04.003","journal-title":"Saudi Pharm J"},{"key":"11026_CR32","doi-asserted-by":"publisher","first-page":"105193","DOI":"10.1016\/j.arabjc.2023.105193","volume":"16","author":"M Er-rajy","year":"2023","unstructured":"Er-rajy M, Mujwar S, Imtara H et al (2023) Design of novel anti-cancer agents targeting COX-2 inhibitors based on computational studies. Arab J Chem 16:105193. https:\/\/doi.org\/10.1016\/j.arabjc.2023.105193","journal-title":"Arab J Chem"},{"key":"11026_CR33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/acs.jmedchem.9b01741","volume":"63","author":"WF Tear","year":"2020","unstructured":"Tear WF, Bag S, Diaz-Gonzalez R et al (2020) Selectivity and physicochemical optimization of repurposed pyrazolo[1,5- b ]pyridazines for the treatment of human african trypanosomiasis. J Med Chem 63:756\u2013783. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01741","journal-title":"J Med Chem"},{"key":"11026_CR34","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1021\/jm040063i","volume":"47","author":"FX Tavares","year":"2004","unstructured":"Tavares FX, Boucheron JA, Dickerson SH et al (2004) N -Phenyl-4-pyrazolo[1,5- b ]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J Med Chem 47:4716\u20134730. https:\/\/doi.org\/10.1021\/jm040063i","journal-title":"J Med Chem"},{"key":"11026_CR35","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1016\/j.bmcl.2008.09.069","volume":"18","author":"KL Stevens","year":"2008","unstructured":"Stevens KL, Reno MJ, Alberti JB et al (2008) Synthesis and evaluation of pyrazolo [1, 5-b] pyridazines as selective cyclin dependent kinase inhibitors. Bioorg Med Chem Lett 18:5758\u20135762. https:\/\/doi.org\/10.1016\/j.bmcl.2008.09.069","journal-title":"Bioorg Med Chem Lett"},{"key":"11026_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1021\/acsmedchemlett.9b00633","volume":"11","author":"F Prati","year":"2020","unstructured":"Prati F, Buonfiglio R, Furlotti G et al (2020) Optimization of indazole-based GSK-3 inhibitors with mitigated hERG issue and in vivo activity in a mood disorder model. ACS Med Chem Lett 11:825\u2013831. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00633","journal-title":"ACS Med Chem Lett"},{"key":"11026_CR37","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.bmcl.2010.01.132","volume":"20","author":"D Lesuisse","year":"2010","unstructured":"Lesuisse D, Tiraboschi G, Krick A et al (2010) Design of potent and selective GSK3\u03b2 inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett 20:2344\u20132349. https:\/\/doi.org\/10.1016\/j.bmcl.2010.01.132","journal-title":"Bioorg Med Chem Lett"},{"key":"11026_CR38","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.bmcl.2010.01.114","volume":"20","author":"D Lesuisse","year":"2010","unstructured":"Lesuisse D, Dutruc-Rosset G, Tiraboschi G et al (2010) Rational design of potent GSK3\u03b2 inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett 20:1985\u20131989. https:\/\/doi.org\/10.1016\/j.bmcl.2010.01.114","journal-title":"Bioorg Med Chem Lett"},{"key":"11026_CR39","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.bmc.2005.10.022","volume":"14","author":"N Foloppe","year":"2006","unstructured":"Foloppe N, Fisher LM, Francis G et al (2006) Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. Bioorg Med Chem 14:1792\u20131804. https:\/\/doi.org\/10.1016\/j.bmc.2005.10.022","journal-title":"Bioorg Med Chem"},{"key":"11026_CR40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bmcl.2007.11.064","volume":"18","author":"H-H Ha","year":"2008","unstructured":"Ha H-H, Kim JS, Kim BM (2008) Novel heterocycle-substituted pyrimidines as inhibitors of NF-\u03baB transcription regulation related to TNF-\u03b1 cytokine release. Bioorg Med Chem Lett 18:653\u2013656. https:\/\/doi.org\/10.1016\/j.bmcl.2007.11.064","journal-title":"Bioorg Med Chem Lett"},{"key":"11026_CR41","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s11030-022-10574-7","volume":"27","author":"B Raju","year":"2023","unstructured":"Raju B, Sapra B, Silakari O (2023) 3D-QSAR assisted identification of selective CYP1B1 inhibitors: an effective bioisosteric replacement\/molecular docking\/electrostatic complementarity analysis. Mol Divers 27:2673\u20132693. https:\/\/doi.org\/10.1007\/s11030-022-10574-7","journal-title":"Mol Divers"},{"key":"11026_CR42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/sam.11583","volume":"15","author":"VR Joseph","year":"2022","unstructured":"Joseph VR (2022) Optimal ratio for data splitting. Stat Anal Data Min ASA Data Sci J 15:531\u2013538. https:\/\/doi.org\/10.1002\/sam.11583","journal-title":"Stat Anal Data Min ASA Data Sci J"},{"key":"11026_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/life13010127","volume":"13","author":"M Er-Rajy","year":"2023","unstructured":"Er-Rajy M, El Fadili M, Imtara H et al (2023) 3D-QSAR studies, molecular docking, molecular dynamic simulation, and ADMET proprieties of novel pteridinone derivatives as PLK1 inhibitors for the treatment of prostate cancer. Life 13:127. https:\/\/doi.org\/10.3390\/life13010127","journal-title":"Life"},{"key":"11026_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29756","author":"BB Rudresh","year":"2024","unstructured":"Rudresh BB, Tater AK, Barot V et al (2024) Development and experimental validation of 3D QSAR models for the screening of thyroid peroxidase inhibitors using integrated methods of computational chemistry. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29756","journal-title":"Heliyon"},{"key":"11026_CR45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0169-7439(01)00155-1","volume":"58","author":"S Wold","year":"2001","unstructured":"Wold S, Sj\u00f6str\u00f6m M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst 58:109\u2013130. https:\/\/doi.org\/10.1016\/S0169-7439(01)00155-1","journal-title":"Chemom Intell Lab Syst"},{"key":"11026_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0169-7439(93)85002-X","volume":"18","author":"S De Jong","year":"1993","unstructured":"De Jong S (1993) SIMPLS: an alternative approach to partial least squares regression. Chemom Intell Lab Syst 18:251\u2013263. https:\/\/doi.org\/10.1016\/0169-7439(93)85002-X","journal-title":"Chemom Intell Lab Syst"},{"key":"11026_CR47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1021\/ci025626i","volume":"43","author":"DM Hawkins","year":"2003","unstructured":"Hawkins DM, Basak SC, Mills D (2003) Assessing model fit by cross-validation. J Chem Inf Comput Sci 43:579\u2013586. https:\/\/doi.org\/10.1021\/ci025626i","journal-title":"J Chem Inf Comput Sci"},{"key":"11026_CR48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11224-022-01913-3","volume":"33","author":"M Er-rajy","year":"2022","unstructured":"Er-rajy M, El Fadili M, Hadni H et al (2022) 2D-QSAR modeling, drug-likeness studies, ADMET prediction, and molecular docking for anti-lung cancer activity of 3-substituted-5-(phenylamino) indolone derivatives. Struct Chem 33:973\u2013986. https:\/\/doi.org\/10.1007\/s11224-022-01913-3","journal-title":"Struct Chem"},{"key":"11026_CR49","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ejmech.2017.08.053","volume":"139","author":"G Floresta","year":"2017","unstructured":"Floresta G, Rescifina A, Marrazzo A et al (2017) Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands. Eur J Med Chem 139:884\u2013891. https:\/\/doi.org\/10.1016\/j.ejmech.2017.08.053","journal-title":"Eur J Med Chem"},{"key":"11026_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1023\/A:1025386326946","volume":"17","author":"A Golbraikh","year":"2003","unstructured":"Golbraikh A, Shen M, Xiao Z et al (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17:241\u2013253. https:\/\/doi.org\/10.1023\/A:1025386326946","journal-title":"J Comput Aided Mol Des"},{"key":"11026_CR51","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1080\/07391102.2023.2226723","volume":"42","author":"S Andole","year":"2024","unstructured":"Andole S, Thumma G, Alavala RR, Gangarapu K (2024) Field-based 3D-QSAR for tyrosine protein kinase JAK-2 inhibitors. J Biomol Struct Dyn 42:5321\u20135333. https:\/\/doi.org\/10.1080\/07391102.2023.2226723","journal-title":"J Biomol Struct Dyn"},{"key":"11026_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/ci050357s","volume":"46","author":"T Cheeseright","year":"2006","unstructured":"Cheeseright T, Mackey M, Rose S, Vinter A (2006) Molecular field extrema as descriptors of biological activity: definition and validation. J Chem Inf Model 46:665\u2013676. https:\/\/doi.org\/10.1021\/ci050357s","journal-title":"J Chem Inf Model"},{"key":"11026_CR53","doi-asserted-by":"publisher","first-page":"9470","DOI":"10.3390\/ijms21249470","volume":"21","author":"D Gentile","year":"2020","unstructured":"Gentile D, Floresta G, Patamia V et al (2020) An integrated pharmacophore\/docking\/3D-QSAR approach to screening a large library of products in search of future botulinum neurotoxin A inhibitors. Int J Mol Sci 21:9470. https:\/\/doi.org\/10.3390\/ijms21249470","journal-title":"Int J Mol Sci"},{"key":"11026_CR54","doi-asserted-by":"publisher","first-page":"W442","DOI":"10.1093\/nar\/gkw287","volume":"44","author":"J Sunseri","year":"2016","unstructured":"Sunseri J, Koes DR (2016) Pharmit: interactive exploration of chemical space. Nucleic Acids Res 44:W442\u2013W448. https:\/\/doi.org\/10.1093\/nar\/gkw287","journal-title":"Nucleic Acids Res"},{"key":"11026_CR55","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/molecules25092163","volume":"25","author":"R Buonfiglio","year":"2020","unstructured":"Buonfiglio R, Prati F, Bischetti M et al (2020) Discovery of novel imidazopyridine GSK-3\u03b2 inhibitors supported by computational approaches. Molecules 25:2163. https:\/\/doi.org\/10.3390\/molecules25092163","journal-title":"Molecules"},{"key":"11026_CR56","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/acs.jmedchem.8b01925","volume":"62","author":"MR Bauer","year":"2019","unstructured":"Bauer MR, Mackey MD (2019) Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein-ligand complexes. J Med Chem 62:3036\u20133050. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01925","journal-title":"J Med Chem"},{"key":"11026_CR57","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449\u2013461. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"},{"key":"11026_CR58","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.arabjc.2017.09.009","volume":"13","author":"A Balupuri","year":"2020","unstructured":"Balupuri A, Balasubramanian PK, Cho SJ (2020) 3D-QSAR, docking, molecular dynamics simulation and free energy calculation studies of some pyrimidine derivatives as novel JAK3 inhibitors. Arab J Chem 13:1052\u20131078. https:\/\/doi.org\/10.1016\/j.arabjc.2017.09.009","journal-title":"Arab J Chem"},{"key":"11026_CR59","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/08927022.2021.1888948","volume":"47","author":"G Saini","year":"2021","unstructured":"Saini G, Dalal V, Gupta DN et al (2021) A molecular docking and dynamic approach to screen inhibitors against ZnuA1 of Candidatus Liberibacter asiaticus. Mol Simul 47:510\u2013525. https:\/\/doi.org\/10.1080\/08927022.2021.1888948","journal-title":"Mol Simul"},{"key":"11026_CR60","doi-asserted-by":"publisher","first-page":"101305","DOI":"10.1016\/j.imu.2023.101305","volume":"41","author":"MAS Khan","year":"2023","unstructured":"Khan MAS, Miah MI, Islam Z et al (2023) Molecular docking and dynamics simulation study of medicinal fungi derived secondary metabolites as potential inhibitor for COVID-19 treatment. Inform Med Unlocked 41:101305. https:\/\/doi.org\/10.1016\/j.imu.2023.101305","journal-title":"Inform Med Unlocked"},{"key":"11026_CR61","doi-asserted-by":"publisher","first-page":"e202400255","DOI":"10.1002\/cbdv.202400255","volume":"21","author":"P Salaria","year":"2024","unstructured":"Salaria P, Reddy MA (2024) Network pharmacology approach to identify the calotropis phytoconstituents\u2019 potential epileptic targets and evaluation of molecular docking, MD simulation, and MM-PBSA performance. Chem Biodivers 21:e202400255. https:\/\/doi.org\/10.1002\/cbdv.202400255","journal-title":"Chem Biodivers"},{"key":"11026_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13205-024-03948-1","volume":"14","author":"P Salaria","year":"2024","unstructured":"Salaria P, Subrahmanyeswara Rao NN, Dhameliya TM, Amarendar Reddy M (2024) In silico investigation of potential phytoconstituents against ligand- and voltage-gated ion channels as antiepileptic agents. 3 Biotech 14:99. https:\/\/doi.org\/10.1007\/s13205-024-03948-1","journal-title":"3 Biotech"},{"key":"11026_CR63","doi-asserted-by":"publisher","first-page":"108003","DOI":"10.1016\/j.compbiolchem.2023.108003","volume":"108","author":"I Habib","year":"2024","unstructured":"Habib I, Chohan TA, Chohan TA et al (2024) Integrated computational approaches for designing potent pyrimidine-based CDK9 inhibitors: 3D-QSAR, docking, and molecular dynamics simulations. Comput Biol Chem 108:108003. https:\/\/doi.org\/10.1016\/j.compbiolchem.2023.108003","journal-title":"Comput Biol Chem"},{"key":"11026_CR64","doi-asserted-by":"publisher","first-page":"e202100782","DOI":"10.1002\/cmdc.202100782","volume":"17","author":"S Gorai","year":"2022","unstructured":"Gorai S, Junghare V, Kundu K et al (2022) Synthesis of dihydrobenzofuro[3,2- b ]chromenes as potential 3CLpro inhibitors of SARS-CoV-2: a molecular docking and molecular dynamics study. ChemMedChem 17:e202100782. https:\/\/doi.org\/10.1002\/cmdc.202100782","journal-title":"ChemMedChem"},{"key":"11026_CR65","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s11224-022-01967-3","volume":"33","author":"R Kaur Bijral","year":"2022","unstructured":"Kaur Bijral R, Singh I, Manhas J, Sharma V (2022) Discovery of EGFR kinase\u2019s T790M variant inhibitors through molecular dynamics simulations, PCA-based dimension reduction, and hierarchical clustering. Struct Chem 33:1957\u20131964. https:\/\/doi.org\/10.1007\/s11224-022-01967-3","journal-title":"Struct Chem"},{"key":"11026_CR66","doi-asserted-by":"publisher","first-page":"102787","DOI":"10.1016\/j.bcab.2023.102787","volume":"51","author":"SH Abdullahi","year":"2023","unstructured":"Abdullahi SH, Uzairu A, Danazumi AU et al (2023) Computational design of quinoxaline molecules as VEGFR-2 inhibitors: QSAR modelling, pharmacokinetics, molecular docking, and dynamics simulation studies. Biocatal Agric Biotechnol 51:102787. https:\/\/doi.org\/10.1016\/j.bcab.2023.102787","journal-title":"Biocatal Agric Biotechnol"},{"key":"11026_CR67","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1007\/s00044-013-0513-8","volume":"22","author":"A Kumari","year":"2013","unstructured":"Kumari A, Kaur M, Bahia MS, Silakari O (2013) 3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase (cFMS): implementation of field-based molecular alignment. Med Chem Res 22:5167\u20135183. https:\/\/doi.org\/10.1007\/s00044-013-0513-8","journal-title":"Med Chem Res"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11026-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:03:58Z","timestamp":1758719038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11026-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["11026"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11026-0","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This is an in silico study and does not require ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}